Measles virus-specific antibody levels in individuals in Argentina who received a one-dose vaccine

Journal of Clinical Microbiology

Volumn 44, Issue 8, 2006, Pages 2733-2738

  Argüelles, Marcelo H ^a,b   Orellana, Mariana L ^a,c   Castello, Alejandro A ^a   Villegas, Guillermo A ^d   Masini, Matilde ^a   Belizan, Alejandra L ^a,c   Ayala, Silvia González ^e   Vera, Osmar D ^a   Glikmann, Graciela ^a  

^a UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^c ANPCyT   (Argentina)

^d Centro de Virologia Animal   (Argentina)

^e Hospital de Ninos Sor Maria Ludovica   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; INACTIVATED VACCINE; MEASLES ANTIBODY; MEASLES VACCINE; TETANUS TOXOID;

ADOLESCENT; ADULT; AGE; ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARGENTINA; ARTICLE; CHILD; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC KIT; ENZYME IMMUNOASSAY; ERADICATION THERAPY; HUMAN; IMMUNE STATUS; MAJOR CLINICAL STUDY; MEASLES; MEASLES VACCINATION; MEASLES VIRUS; NONHUMAN; PRIORITY JOURNAL; REINFECTION; SINGLE DRUG DOSE; VIRUS NEUTRALIZATION;

ADOLESCENT; AGE FACTORS; ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; ARGENTINA; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN G; INFANT; MALE; MEASLES; MEASLES VACCINE; MEASLES VIRUS; NEUTRALIZATION TESTS; STATISTICS; TETANUS TOXOID;

MEASLES VIRUS;

EID: 33747179797     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00980-05     Document Type: Article

References (58)

1. Aaby, P., J. Bukh, J. Leerhoy, I. M. Lisse, C. H. Mordhost, and R. Pedersen. 1986. Vaccinated children get milder measies infection: a community study from Guinea-Bissau. J. Infect. Dis. 154:858-863.
2. Albrecht, P., F. A. Ennis, E. J. Saltzman, and S. Krugman. 1977. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J. Pediatr. 91:715-718.
3. Albrecht, P., K. Herrmann, and G. R. Burns. 1981. Role of virus strain in conventional and enhanced measles plaque neutralization test. J. Virol. Methods 3:251-260.
4. Arya, S. C., and N. Agarwal. 2004. Efficacy of measles vaccine interlinked with potency and storage. Acta Trop. 90:223-225.
5. Atkinson, W. L., W. A. Orenstein, and S. Krugman. 1992. The resurgence of measles in the United States, 1989-1990. Annu. Rev. Med. 43:451-463.
6. Bautista-López, N. L., A. Vaisberg, R. Kanashiro, H. Hernández, and B. J. Ward. 2001. Immune response to measles vaccine in Peruvian children. Bull. W. H. O. 79:1038-1046.
7. Bellini, W. J., D. E. McFalin, G. D. Silver, E. S. Mingioli, and H. F. McFarland. 1981. Immune reactivity of purified hemagglutinin of measles virus. Infect. Immun. 32:1051-1057.
8. Black, F. L., L. L. Berman, J. M. Borgono, R. A. Capper, A. A. Carvalho, C. Collins, O. Glover, Z. Hyazi, D. L. Jacobson, and Y. L. Lee. 1986. Geographic variation in infant loss of maternal measles antibody and in prevalence of rubella antibody. Am. J. Epidemiol. 124:442-452.
9. Bottiger, M., B. Christenson, V. Romanus, J. Taranger, and A. Strandell. 1987. Swedish experience of two-dose vaccination programme aiming at eliminating measles, mumps and rubella. Br. Med. J. Clin. Res. 295:1264-1267.
10. Bouche, F., W. Ammerlaan, F. Berthet, S. Houard, F. Schneider, and C. P. Muller. 1998. Immunosorbent assay based on recombinant hemagglutinin protein produced in a high-efficiency mammalian expression system for surveillance of measles immunity. J. Clin. Microbiol. 36:721-726.
11. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 7:248-254.
12. Broliden, K., B. Leven, M. Arneborn, and M. Bötigger. 1998. Immunity to measles before and after MMR booster or primary vaccination at 12 years of age in the first generation offered the 2-dose immunization programme. Scand. J. Infect. Dis. 30:23-27.
13. Calvert, N., F. Cutts, R. Irving, D. Brown, J. Marsh, and E. Miller. 1996. Measles immunity and response to revaccination among secondary school children in Cumbria. Epidemiol. Infect. 116:65-70.
14. Chen, R. T., L. E. Markowitz, P. Albrecht, J. A. Stewart, L. M. Mofenson, S. R. Preblud, and W. A. Orenstein. 1990. Measles antibody: re-evaluation of protective titers. J. Infect. Dis. 162:1036-1042.
15. Ciofi degli Atti, M. L., F. Fabi, S. Salmaso, R. Pizzuti, and E. de Campora. 2003. Measles epidemic attributed to inadequate vaccination coverage: Campania, Italy, 2002. Morb. Mortal. Wkly. Rep. 52:1044-1047.
16. Crovari, P., G. Gabutti, G. Giammanco, P. Dentico, A. R. Moiraghi, F. Ponzio, R. Soncini, et al. 2000. Reactogenicity and immunogenicity of a new combined measles-mumps-rubella vaccine; results of a multicentre trial. Vaccine 18:2796-2803.
17. Cutts, F. T. 1993. The immunological basis for immunization series. Module 7: measles. WHO/EPI/GEN/93.17. World Health Organization, Geneva, Switzerland.
18. Cutts, F. T., M. Grabowsky, and L. E. Markowitz. 1995. The effect of dose and strain of live attenuated measles vaccines on serological responses in young infants. Biologicals 23:95-106.
19. Davidkin, I., and M. Valle. 1998. Vaccine-induced measles virus antibodies after two doses of combined measles, mumps and rubella vaccine: a 12-year follow-up in two cohorts. Vaccine 16:2052-2057.
20. Domínguez, A., J. Vidal, P. Plans, G. Carmona, P. Godoy, J. Batalla, and L. Salleras. 1999. Measles immunity and vaccination policy in Catalonia. Vaccine 17:530-534.
21. Gans, H. A., L. L. Yasukawa, A. Alderson, M. Rinky, R. De Hovitz, J. Beeler, S. Andet, Y. Maldonado, and A. M. Arvin. 2004. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States. J. Infect. Dis. 190:83-90.
22. Garenne, M., O. Leroy, J. P. Beau, and I. Sene. 1993. High-liter measles virus vaccines: protection evaluation, p. 119-131. in E. Kurstak (ed.), Measles and poliomyelitis: vaccines, immunization, and control. Springer-Verlag, Vienna, Austria.
23. Garly, M. L., C. Bale, C. L. Martins, M. Monteiro, E. George, M. Kidd, D. Dias, P. Aaby, and H. C. Whittle. 2001. Measles antibody responses after early two dose trials in Guinea-Bissau with Edmonston-Zagreb and Schwarz standard-titre measles vaccine: better antibody increase from booster dose of the Edmonston-Zagreb vaccine. Vaccine 19:1951-1959.
24. Gay, N. J. 2000. Eliminating measles: no quick fix. Bull. W. H. O. 78:949.
25. Glikmann, G., S. N. Chen, C. H. Mordhorst, and C. Koch. 1995. Monoclonal antibodies for the rapid diagnosis of infiuenza-B virus infections by ELISA: production and characterization. Clin. Diagn. Virol. 4:27-42.
26. Glikmann, G., I. Pedersen, and C. H. Mordhorst. 1987. Prevalence of IgG-antibodies to mumps and measles virus in non-vaccinated children. Dan. Meci. Bull. 55:105-107.
27. Hussey, G. D., E. A. Goddard, J. Hughes, J. J. Ryon, M. Kerran, E. Carelse, P. M. Strebel, L, E. Markowitz, J. Moodie, P. Barron, Z. Latief, R. Sayed, D. Beatty, and D. E. Griffin. 1996. The effects of Edmonston-Zagreb and Schwarz measles vaccine on immune responses of infants. J. Infect., Dis. 173:1320-1326.
28. Jensen, T. G., H. Whittle, C. H. Mordhorst, I. R. Pedersen, J. Thaarup, A. Poulsen, M. Sodemann, M. Jakobsen, L. Brink, U. Gansted, A. Permin, M. C. da Silva, and P. Aaby. 1994. Trials of Edmonston-Zagreb measles vaccine in Guinea-Bissau: serological responses following vaccination with Edmonston-Zagreb strain at 4-8 months versus vaccination with the Schwarz strain at 9-12 months. Vaccine 12:1026-1031.
29. Johnson, C. E., A. Darbari, D. S. Darbari, D. Nalin, J. Whitwell, L. W. Chui, M. A. Cleves, and M. L. Kumar, 2000. Measles vaccine immunogenicity and antibody persistence in 12 vs 15-month old infants. Vaccine 18:2411-2415.
30. Johnson, H., I. B. Hillary, G. McQuoid, and B. Gilmer. 1995. MMR vaccination, measles epidemiology and sero-surveillance in the Republic of Ireland. Vaccine 13:533-537.
31. Kiepiela, P., H. M. Coovadia, W. E. Loening, P. Coward, and S. S. Abdool Karim. 1991. Loss of maternal measles antibody in black South African infants in the first year of life-implications for age vaccination. S. Afr. Med, J. 79:145-148.
32. Koch, C. 1997. Immunologisk Udviklingsafdeling IUA 006, p. 1-7. In Arsberetning 1997. Statens Seruminstitut, Copenhagen, Denmark. (In Danish.)
33. Kumar, M. L., C. E. Johnson, L. W. Chui, J. K. Whitwell, B. Staehle, and D. Nalin. 1998. Immune response to measles vaccine in 6-month-old infants of measles seronegative mothers. Vaccine 16:2047-2051.
34. Mast, E. E., J. L. Berg, L. P. Hanrahan, J. T. Wassell, and J. P. Davies. 1990. Risk factors for measles in a previously vaccinated population and cost-effectiveness of revaccination strategies. JAMA 264:2529-2533.
35. Miller, E., A. Hill, P. Morgan-Capner, T. Forsey, and M. Rush. 1995. Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines. Vaccine 13:799-802.
36. Mossong, J., and C. P. Muller. 2003. Modelling measles re-emergence as a result of waning of immunity in vaccinated populations. Vaccine 21:4597-4603.
37. Mossong, J., C. J. O'Callaghan, and S. Ratnam. 2000. Modeling antibody response to measles vaccine and subsequent waning of immunity in a low exposure population. Vaccine 19:523-529.
38. Naniche, D., M. Garenne, C. Rae, M. Manchester, R. Buchta, S. K. Brodine, and M. B. A. Oldstine. 2004. Decrease in measles virus-specific CD4 T cell memory in vaccinated subjects. J. Infect. Dis. 190:1387-1395.
39. Nates, S. V., M. O. Giordano, S. I. Medeot, L. C. Martinez, A. M. Baudagna, E. Naretto, P. Garrido, and C. D. de Wolff. 1998. Loss of maternally derived measles immunity in Argentine infants. Pediatr. Infect. Dis. J. 17:313-316.
40. National Vaccine Advisory Committee. 1991. The measles epidemic. The problems, barriers, and recommendations. JAMA 266:1547-1552.
41. Nicoara, C., K. Zäch, D. Trachsel, D. Germann, and L. Matter. 1999. Decay of passively maternal antibodies against measles, mumps, and rubella viruses. Clin. Diagn. Lab. Immunol. 6:868-871.
42. Pan American Health Organization Division of Vaccines and Immunization (HVP). 2000. Interrupting measles transmission in the Americas. Epidemiological bulletin 21. [Online.] http://www.paho.org/english/sha/be_v21n4 -measles.htm.
43. Pannuti, C. S., R. J. Morello, J. C. de Moraes, S. P. Curti, A. M. S. Afonso, M. C. C. Camargo, and V. A. U. F. de Souza. 2004. Identification of primary and secondary measles vaccine failures by measurement of immunoglobulin G avidity in measles cases during the 1997 São Paulo epidemic. Clin. Diagn. Lab. Immunol. 11:119-122.
44. Paunio, M., K. Hedman, I. Davidkin, M. Valle, O. P. Heinonen, P. Leiniki, A. Salmi, and H. Peltola. 2000. Secondary measles vaccine failures identified by measurement of IgG avidity: high occurrence among teenagers vaccinated at a young age. Epidemiol. Infect. 124:263-271.
45. Pedersen, I. R., C. H. Mordhost, G. Glikmann, and H. von Magnus. 1989. Subclinical measles infection in vaccinated seropositive individuals in arctic Greenland. Vaccine 7:345-348.
46. Peltola, H., I. Davidkin, M. Valle, M. Paunio, T. Hovi, O. P. Heinonen, and P. Leinikki. 1997. No measles in Finland, Lancet 350:1364-1365.
47. Ratnam, S., V. Gadag, R. West, J. Burns, E. Oates, F. Stead, and N. Bouilianne. 1995. Comparison of commercial enzyme immunoassay kits with plaque reduction neutralization test for detection of measles virus antibody. J. Clin. Microbiol. 33:811-815.
48. Song, M. K., C. J. Vindurampulle, A. V. E. Capozzo, J. Ulmer, J. M. Polo, M. Pasetti, E. M. Barry, and M. M. Levine. 2005. Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins. J. Virol. 79:9854-9861.
49. St. Sauer, J. L., R. M. Jacobson, R. A. Vierkant, S. J. Jacobsen, E. M. Green, D. J. Schaid, and G. A. Poland. 2001. Correlation between measles, mumps, and rubella serum antibody levels in Olmsted County school children. Vaccine 19:1363-1368.
50. Sushil, J., G. Lalitha, K. George, and A. Joseph. 2004. Serological response to early measles vaccination. J. Trop. Pediatr. 50:175-177.
51. Sutcliffe, P. A., and E. Rea. 1996. Outbreak of measles in a highly vaccinated secondary school population. Can. Med. Assoc. J. 155:1407-1413.
52. Tischer, A., and E. Gerike. 2000. Immune response after primary and revaccination with different combined vaccines against measles, mumps and rubella. Vaccine 18:1382-1392.
53. Udem, S. A. 1984. Measles virus: conditions for the propagation and purification of infectious virus in high yield. J. Virol. Methods 8:123-136.
54. UytdeHaag, F. G., R. S. van Binnendijk, M. J. Kenter, and A. D. Osterhaus. 1994. Cytotoxic T lymphocytes responses against measles virus. Curr. Top. Microbiol. Immunol. 189:151-167.
55. van Binnendijk, R. S., C. A. van Baalen, M. C. Poelen, P. de Vries, J. Boes, V. Cerundolo, A. D. Osterhaus, and F. G. UytdeHaag. 1992. Measles virus transmembrane fusion protein synthesized de novo or presented in immunostimulating complexes is endogenously processed for HLA class I- and class II-restricted cytotoxic T cell recognition. J. Exp. Med. 176:119-128.
56. van Binnendijk, R. S., J. P. M. Versteeg-van Oosten, M. C. M. Poelen, H. F. Brugghe, P. Hoogerhout, A. D. M. E. Osterhaus, and F. G. C. M. Uytdehaag. 1993. Human HLA class I- and class II-restricted cloned cytotoxic T lymphocytes identify a cluster of epitopes on the measles virus fusion protein. J. Virol. 67:2276-2284.
57. Villegas, G. A., M. H. Argüelles, A. A. Castello, N. Jiménez Mas, and G. Glikmann. 2002. A rapid method to produce high yields of purified rotavirus particles. J. Virol. Methods 104:9-19.
58. Youwang, Y., W. Ping, and C. Feng. 2001. Serological and epidemiological effects and influence factors of primary immunizations with current live attenuated measles vaccine (Hu 191) among infants aged 6-15 months. Vaccine 19:1998-2005.